Alpha-particles for targeted therapy

Advanced Drug Delivery Reviews

Volumn 60, Issue 12, 2008, Pages 1402-1406

  Sgouros, George ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Alpha particle; Dosimetry; Targeted therapy

Indexed keywords

CELL CULTURE; DECAY (ORGANIC); DEPOSITS; DNA; ELECTROTHERAPEUTICS; GENES; HEALTH; HELIUM; INERT GASES; NUCLEIC ACIDS; ORGANIC ACIDS; RADIATION; RADIATION EFFECTS; RADIOISOTOPES; RADIOMETRY;

ABSORBED DOSE; ALPHA-PARTICLES; BIOLOGICAL EFFECTS; CELL NUCLEUS; CLINICAL TRIALS; DOUBLE-STRANDED DNA BREAKS; ELSEVIER (CO); EXTERNAL BEAMS; EXTERNAL RADIOTHERAPY; HELIUM NUCLEUS; MICRO DOSIMETRY; NEW CLASS; PARTICLE DECAYS; PARTICLE RADIATION; STOCHASTIC NATURE; TARGET VOLUMES;

ANIMAL CELL CULTURE;

ACTINIUM 225; BISMUTH 213; LEAD 209; MONOCLONAL ANTIBODY TENASCIN AT 211; POLONIUM 213; RADIOISOTOPE; RADIUM 223; THALLIUM 209;

ACUTE GRANULOCYTIC LEUKEMIA; ALPHA RADIATION; CLINICAL TRIAL; DNA DAMAGE; DOUBLE STRANDED DNA BREAK; DRUG EFFICACY; ELECTRON; EXTERNAL BEAM RADIOTHERAPY; GLIOBLASTOMA; HUMAN; MICRODOSIMETRY; PRIORITY JOURNAL; RELATIVE BIOLOGIC EFFECTIVENESS; REVIEW;

ALPHA PARTICLES; ANIMALS; CLINICAL TRIALS AS TOPIC; HUMANS; NEOPLASMS; RADIOTHERAPY DOSAGE; RELATIVE BIOLOGICAL EFFECTIVENESS;

EID: 46949111791     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.addr.2008.04.007     Document Type: Review

References (44)

1. McDevitt M.R., Sgouros G., Finn R.D., Humm J.L., Jurcic J.G., Larson S.M., et al. Radioimmunotherapy with alpha-emitting nuclides. Eur. J. Nucl. Med. 25 9 (1998) 1341-1351
2. Barendsen G.W., and Beusker T.L.J. Effects of different ionizing radiations on human cells in tissue culture. 1. Irradiation techniques and dosimetry. Radiat. Res. 13 6 (1960) 832-840
3. Barendsen G.W., Beusker T.L.J., Vergroesen A.J., and Budke L. Effect of different ionizing radiations on human cells in tissue culture. 2. Biological experiments. Radiat. Res. 13 6 (1960) 841-849
4. Barendsen G.W., and Vergroesen A.J. Irradiation of human cells in tissue culture with alpha-rays, beta-rays and X-rays. Int. J. Radiat. Biol. Relat. Stud. Phys. Chem. Med. 2 4 (1960) 441
5. Barendsen G.W. Dose-survival curves of human cells in tissue culture irradiated with alpha-, beta-, 20-kV X- and 200-kV X-radiation. Nature 193 4821 (1962) 1153-&.
6. Barendsen G.W., Walter H.M.D., Bewley D.K., and Fowler J.F. Effects of different ionizing radiations on human cells in tissue culture. 3. Experiments with cyclotron-accelerated alpha-particles and deuterons. Radiat. Res. 18 1 (1963) 106-119
7. Barendsen G.W., and Walter H.M.D. Effects of different ionizing radiations on human cells in tissue culture. 4. Modification of radiation damage. Radiat. Res. 21 2 (1964) 314-329
8. Barendsen G.W. Modification of radiation damage by fractionation of dose anoxia +chemical protectors in relation to LET. Ann. N.Y. Acad. Sci. 114 A1 (1964) 96-114
9. Barendsen G.W. Impairment of the proliferative capacity of human cells in culture by alpha-particles with differing linear-energy transfer. Int. J. Radiat. Biol. Relat. Stud. Phys. Chem. Med. 8 5 (1964) 453-466
10. Jurcic J.G., Larson S.M., Sgouros G., McDevitt M.R., Finn R.D., Divgi C.R., et al. Targeted alpha particle immunotherapy for myeloid leukemia. Blood 100 4 (2002) 1233-1239
11. Jurcic J.G., McDevitt M.R., Sgouros G., Ballangrud A., Finn R.D., Geerlings M.W., et al. Targeted alpha-particle therapy for myeloid leukemias: a phase I trial of bismuth-213-HuM195 (anti-CD33). Blood 90 10 (1997) 2245
12. Geerlings M.W., Kaspersen F.M., Apostolidis C., and van der Hout R. The feasibility of 225Ac as a source of alpha-particles in radioimmunotherapy. Nucl. Med. Common. 14 2 (1993) 121-125
13. Zalutsky M.R., Cokgor I., Akabani G., Friedman H.S., Coleman R.E., Friedman A.H., et al. Phase I trial of alpha-particle-emitting astatine-211 labeled chimeric anti-tenascin antibody in recurrent malignant glioma patients. Annu. Meet. Am. Assoc. Cancer Res., Proc. 41 (2000) 544
14. Zalutsky M.R., and Vaidyanathan G. Astatine-211-labeled radiotherapeutics: an emerging approach to targeted alpha-particle radiotherapy. Curr. Pharm. Des. 6 14 (2000) 1433-1455
15. Mulford D.A., Scheinberg D.A., and Jurcic J.G. The promise of targeted {alpha}-particle therapy. J. Nucl. Med. 46 Suppl 1 (2005) 199S-204S
16. Jurcic J.G. Antibody therapy for residual disease in acute myelogenous leukemia. Crit. Rev. Oncol./ Hematol. 38 1 (2001) 37-45
17. Wilbur D.S. Potential use of alpha-emitting radionuclides in the treatment of cancer. Antib. Immunoconjug., Radiopharm. 4 (1990) 85-97
18. Humm J.L., Roeske J.C., Fisher D.R., and Chen G.T.Y. Microdosimetric concepts in radioimmunotherapy. Med. Phys. 20 2 (1993) 535-541
19. Feinendegen L.E., and McClure J.J. Meeting report - alpha-emitters for medical therapy - workshop of the United States Department of Energy - Denver, Colorado, May 30-31, 1996. Radiat. Res. 148 2 (1997) 195-201
20. Kellerer A.M., and Chmelevsky D. Criteria for applicability of LET. Radiat. Res. 63 2 (1975) 226-234
21. Roeske J.C., and Stinchcomb T.G. Dosimetric framework for therapeutic alpha-particle emitters. J. Nucl. Med. 38 12 (1997) 1923-1929
22. Stinchcomb T.G., and Roeske J.C. Values of "S," , and <(z1)2> for dosimetry using alpha-particle emitters. Med. Phys. 26 9 (1999) 1960-1971
23. Roeske J.C., and Stinchcomb T.G. Tumor control probability model for alpha-particle-emitting radionuclides. Radiat. Res. 153 1 (2000) 16-22
24. Loevinger R., Budinger T.F., and Watson E.E. MIRD Primer for Absorbed Dose Calculations, Revised Edition (1991), The Society of Nuclear Medicine, Inc., New York, NY
25. 213Bi-HuM195 (anti-CD33) in patients with leukemia. J. Nucl. Med. 40 11 (1999) 1935-1946
26. Goddu S.M., Howell R.L., Bouchet L.G., Bolch W.E., and Rao D.V. MIRD Cellular S Values (1997), Society of Nuclear Medicine, Reston VA
27. Weber D.A., Eckerman K.F., Dillman L.T., and Ryman J.C. MIRD: Radionuclide Data and Decay Schemes (1989), The Society of Nuclear Medicine, New York
28. Snyder W.S., Fisher H.L., Ford M.R., and Warner G.G. Estimates of absorbed fractions for monoenergetic photon sources uniformly distributed in various organs of a heterogeneous phantom. J. Nucl. Med. 10 3S (1969) 7-52
29. Watchman C.J., Jokisch D.W., Patton P.W., Rajon D.A., Sgouros G., and Bolch W.E. Absorbed fractions for alpha-particles in tissues of trabecular bone: considerations of marrow cellularity within the ICRP reference male. J. Nucl. Med. 46 7 (2005) 1171-1185
30. Bouchet L.G., Jokisch D.W., and Bolch W.E. A three-dimensional transport model for determining absorbed fractions of energy for electrons within trabecular bone. J. Nucl. Med. 40 11 (1999) 1947-1966
31. Snyder W.S., Ford M.R., and Warner G.G. Estimates of specific absorbed fractions for photon sources uniformly distributed in various organs of a heterogeneous phantom. MIRD Pamphlet No. 5, Revised, 5-67. 1978 (1978), The Society of Nuclear Medicine
32. ICRP. ICRP 92: Relative Biological Effectiveness (RBE), Quality Factor (Q), and Radiation Weighting Factor (WR), 92 (2003) ICRP.
33. Jurcic J.G., McDevitt M.R., Pandit-Taskar N., Divgi C.R., Finn R.D., Sgouros G., et al. Alpha-particle immunotherapy for acute myeloid leukemia (AML) with bismuth-213 and actinium-225. Cancer Biother. Radiopharm. 21 4 (2006) 396
34. Mulford D.A., Pandit-Taskar N., McDevitt M.R., Finn R.D., Weiss M.A., Apostolidis C., et al. Sequential therapy with cytarabine and bismuth-213 (Bi-213)-labeled-HuM195 (anti-CD33) for acute myeloid leukemia (AML). Blood 104 11 (2004) 496A
35. Heeger S., Moldenhauer G., Egerer G., Wesch H., Martin S., Nikula T., et al. Alpha-radioimmunotherapy of B-lineage non-Hodgkin's lymphoma using 213Bi-labelled anti-CD19-and anti-CD20-CHX-A″-DTPA conjugates. Abstr. Pap. - Am. Chem. Soc. 225 (2003) U261
36. Phase I Clinical Study on Alpha-therapy for Non-Hodgkin Lymphoma (2004) 04 Jun 28; Dusseldorf, Germany.
37. Kneifel S., Cordier D., Good S., Ionescu M.C.S., Ghaffari A., Hofer S., et al. Local targeting of malignant gliomas by the diffusible peptidic vector 1,4,7,10-tetraazacyclododecane-1-glutaric acid-4,7,10-triacetic acid-substance P. Clin. Cancer Res. 12 12 (2006) 3843-3850
38. Allen B.J., Raja C., Rizvi S., Li Y., Tsui W., Graham P., et al. Intralesional targeted alpha therapy for metastatic melanoma. Cancer Biol. Ther. 4 12 (2005) 1318-1324
39. Zalutsky M.R., Reardon D.A., Akabani G., Friedman A.H., and Herndon J.E. Astatine-211 labeled human/mouse chimeric anti-tenascin monoclonal antibody via surgically created resection cavities for patients with recurrent glioma: phase I study. [abstract]. Neuro-Oncology 4 (2002) S10
40. Zalutsky M.R., and Pozzi O.R. Radioimmunotherapy with alpha-particle emitting radionuclides. Q. J. Nucl. Med. Mol. Imaging 48 4 (2004) 289-296
41. Bruland O.S., Nilsson S., Fisher D.R., and Larsen R.H. High-linear energy transfer irradiation targeted to skeletal metastases by the alpha-emitter Ra-223: adjuvant or alternative to conventional modalities?. Clin. Cancer Res. 12 20 (2006) 6250S-6257S
42. Nilsson S., Larsen R.H., Fossa? S.D., Balteskard L., Borch K.W., Westlin J.E., et al. First clinical experience with alpha-emitting radium-223 in the treatment of skeletal metastases. Clin. Cancer Res. 11 12 (2005) 4451-4459
43. McDevitt M.R., Ma D., Lai L.T., Simon J., Borchardt P., Frank R.K., et al. Tumor therapy with targeted atomic nanogenerators. Science 294 5546 (2001) 1537-1540
44. Rosenblat T.L., McDevitt M.R., Pandit-Taskar N., Carrasquillo J.A., Chanel S., Frattinit M.G., et al. Phase I Trial of the Targeted Alpha-particle Nano-generator Actinium-225 (225Ac)-HuM195 (anti-CD33) in Acute Myeloid Leukemia (AML) (2007) [abstract]. Proc ASH.